Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe (Q41922681)

14 October 2017

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe (English)

1 reference

14 October 2017

9

Carole Seguin-Devaux

0 references

Matti Maimets

22

Matti Maimets

0 references

Jean-Michel Pawlotsky

28

Jean-Michel Pawlotsky

0 references

Alison D Marshall

Alison D Marshall

1

0 references

Stine Nielsen

Stine Nielsen

3

0 references

Anne Øvrehus

Anne Øvrehus

27

0 references

Adriana Vince

Adriana Vince

38

0 references

Jeffrey V. Lazarus

Jeffrey V Lazarus

40

0 references

Leondios G Kostrikis

Leondios G Kostrikis

20

0 references

Carlos Roncero

Carlos Roncero

31

0 references

Matthew Hickman

Matthew Hickman

15

0 references

Robert Flisiak

Robert Flisiak

10

0 references

Evan B Cunningham

Evan B Cunningham

2

0 references

Gregory J Dore

39

Gregory J Dore

1 reference

14 October 2017

41

Jason Grebely

1 reference

14 October 2017

Alessio Aghemo

4

1 reference

14 October 2017

Hannu Alho

5

1 reference

14 October 2017

Markus Backmund

6

1 reference

14 October 2017

Philip Bruggmann

7

1 reference

14 October 2017

Olav Dalgard

8

1 reference

14 October 2017

Graham R Foster

11

1 reference

14 October 2017

Liana Gheorghe

12

1 reference

14 October 2017

David Goldberg

13

1 reference

14 October 2017

Ioannis Goulis

14

1 reference

14 October 2017

Patrick Hoffmann

16

1 reference

14 October 2017

Ligita Jancorienė

17

1 reference

14 October 2017

Peter Jarcuska

18

1 reference

14 October 2017

Martin Kåberg

19

1 reference

14 October 2017

Mihály Makara

21

1 reference

14 October 2017

Matti Maimets

22

1 reference

14 October 2017

Rui Tato Marinho

23

1 reference

14 October 2017

Mojca Matičič

24

1 reference

14 October 2017

Suzanne Norris

25

1 reference

14 October 2017

Sigurður Ólafsson

26

1 reference

14 October 2017

Jean-Michel Pawlotsky

28

1 reference

14 October 2017

James Pocock

29

1 reference

14 October 2017

Geert Robaeys

30

1 reference

14 October 2017

Marieta Simonova

32

1 reference

14 October 2017

Jan Sperl

33

1 reference

14 October 2017

Michele Tait

34

1 reference

14 October 2017

Ieva Tolmane

35

1 reference

14 October 2017

Stefan Tomaselli

36

1 reference

14 October 2017

Marc van der Valk

37

1 reference

14 October 2017

International Network on Hepatitis in Substance Users (INHSU)

42

1 reference

14 October 2017

language of work or name

English

0 references

publication date

3 October 2017

1 reference

The lancet. Gastroenterology & hepatology

14 October 2017

1 reference

14 October 2017

3

0 references

page(s)

125-133

1 reference

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

13 September 2019

issue

2

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Hepatitis C virus therapeutic development: in pursuit of "perfectovir".

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Estimates on HCV disease burden worldwide - filling the gaps

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

EASL Recommendations on Treatment of Hepatitis C 2016

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Epidemiology and natural history of HCV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Outcomes of treatment for hepatitis C virus infection by primary care providers

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

What is killing people with hepatitis C virus infection?

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930284-4

7 January 2021

10.1016/S2468-1253(17)30284-4

Identifiers

DOI

1 reference

14 October 2017

1 reference